Health AI Central
Peer-Reviewed Publication
J Med Econ2026;29(1):2448-2463.December 1, 2026Journal Article

Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden.

Songkai Yan1, Olof Mogard2, Anna Tjärnlund-Wolf3, Fredrik Sjöö3, André Eid4, Jack Ettinger4, Douglass Drelich1, Radovan Tomic5, Stina Johansson3
1CSL Behring, King of Prussia, PA, USA.
2Parexel International, Zürich, Switzerland.
3CSL Behring AB, Stockholm, Sweden.
4Parexel International, London, UK.
5CSL Behring S.p.A., Milan, Italy.
PubMed DOI

Abstract

INTRODUCTION: Etranacogene dezaparvovec (EDZ), a novel one-time gene therapy for severe/moderately severe haemophilia B, provides sustained factor IX (FIX) activity, usually eliminating the need for lifelong replacement therapy. AIM: To evaluate cost-effectiveness of EDZ vs. prophylaxis with eftrenonacog alfa (rFIXFc) in adults with haemophilia B in Sweden. METHODS: A lifetime Markov model (age…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.